Abstract: Methods are provided for predicting the efficacy of midostaurin for the treatment of a cancer in an individual subject or a cohort of patients. The method comprises determining a phosphoproteomic and/or a proteomic signature within a sample obtained from the individual subject wherein the phosphoproteomic and/or proteomic signature provides a personalised prediction for the individual subject of the efficacy of midostaurin for treatment of cancer. This invention has utility in methods for treatment of a range of cancers including acute myeloid leukaemia (AML). Companion diagnostic kits and their use in dosage regimens for the treatment of cancer are also provided.

Abstract: The invention relates to materials and methods for diagnosing liver tumor types, and assessing patient prognosis. Specifically, but not exclusively, the invention concerns the determination of marker protein which enable primary liver tumors to be identified and classified according to the latest WHO classification. Particularly, the invention provides potential markers proteins which allow non-neoplastic and neoplastic hepatocytes and biliary epithelial cells to be distinguished. This allows grading of tumor differentiation to be refined and differential diagnosis of primary liver tumors and pathogenesis of sub-types of cholangiocarcinoma.